<DOC>
	<DOCNO>NCT00551174</DOCNO>
	<brief_summary>This 2-arm study design ass long-term safety tolerability intravenous ( IV ) treatment 2 mg 3 mg Bonviva woman post-menopausal osteoporosis previously complete Bonviva study BM16550 ( DIVA study ; NCT00048074 ) . Patients receive Bonviva either 2 mg IV every 2 month , 3 mg IV every 3 month . Patients also receive daily supplementation vitamin D calcium . The anticipated time study treatment 2+ year , target sample size 500+ individual .</brief_summary>
	<brief_title>A Study Bonviva ( Ibandronate ) Women With Post-Menopausal Osteoporosis Who Have Received Previous Bonviva Treatment</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Ibandronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Successful completion Bonviva study BM16550 ( NCT00048074 ) , least 75 % compliance Ambulatory Patients complete Bonviva study BM16550 ( NCT00048074 ) &gt; 3 month plan start date study Malignant disease diagnose since inclusion previous study Treatment drug affect bone metabolism since inclusion previous study</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
</DOC>